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Original Article
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Background The impact of pandemic H1N1 influenza (pH1N1)
virus in pediatric cancer is uncertain. The objectives of this study
were to characterize the clinical course of pH1N1 and identify
factors associated with severe outcomes.
Methods We conducted a Canadian multicenter retrospective
review of children with cancer and stem cell transplant (SCT)
recipients who were diagnosed with laboratory-confirmed pH1N1
infection between May 1, 2009 and January 31, 2010.
Results We identified 100 (19 in wave 1 and 81 in wave 2) cases

of pH1N1 infection. Median age was 8Æ7 years. 71% had a
hematologic malignancy, and 20% received SCT. Median duration
of fever and illness was 2 and 12Æ5 days, respectively. 51 (51Æ5%)
were hospitalized for a median of 5 days, with no deaths and only
1 requiring admission to the intensive care unit. Radiologically
confirmed pneumonia was diagnosed in 10 (10%). Interruption of
chemotherapy or conditioning occurred in 43 patients. In

multivariable analyses, age <5 years (relative to ‡10 years) and
neutropenia were associated with hospitalization while
neutropenia was associated with pneumonia. Despite oseltamivir
use in 89%, viral shedding was prolonged (median, 46 days) and
often persisted after symptom resolution. However, an extended
treatment course (>5 days) correlated with shortened duration of
viral shedding (P = 0Æ041).
Conclusions pH1N1 infection in pediatric cancer and SCT

patients infrequently caused complications but commonly
interrupted cancer treatment. Persistent shedding of virus after
illness resolution was common. Further research is needed to
verify this finding as it could have implications for treatment
guidelines and infection control practices.
Keywords cancer, child, pandemic H1N1 influenza, stem cell

transplant.
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Introduction
First detected in April of 2009,1 the pandemic H1N1 influenza (pH1N1) virus rapidly spreads globally, triggering the
first pandemic of the 21st century. By August 1, 2010,
more than 214 countries reported laboratory-confirmed
cases to the World Health Organization, including over
18 449 deaths.2
Children with cancer and pediatric hematopoietic stem
cell transplant (SCT) recipients comprise an important
group of immunocompromised patients in whom prolonged viral shedding and serious influenza-associated morbidity are common.3–10 If pH1N1 substantially contributes
to future influenza seasons as may be expected via anti-
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genic drift, an understanding of its clinical course and
severity in pediatric cancer patients in multiple geographic
regions would help inform healthcare needs, provide information to facilitate decision-making regarding cancer treatment interruption, and identify early interventions to
improve outcomes.
An analysis of pooled surveillance data on laboratoryconfirmed pH1N1 cases from 19 countries or administrative regions demonstrated that the odds ratio (OR) for
death given hospitalization was >5 for immunocompromised patients, but did not determine ORs for subgroups
of these patients.11 Several studies of pH1N1 infection in
pediatric cancer patients have yielded conflicting information, with some demonstrating a mild course,12–15 while a
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Brazilian study documented a high mortality rate among
hospitalized cases.16 Almost all of these studies were conducted at single centers, thus raising concerns about the
generalizability of findings.
Consequently, we conducted a Canadian multicenter
retrospective analysis of pH1N1 in pediatric cancer. Our
objectives were to describe the clinical course and identify
factors associated with severe outcomes of children with
cancer or pediatric SCT recipients diagnosed with laboratory-confirmed pH1N1.

Methods
Patients and setting
We identified eligible cases through retrospective review of
virology reports and health records from a base population
of patients cared for by the Divisions of Haematology ⁄
Oncology at six Canadian pediatric referral centers (BC
Children’s Hospital, Vancouver; The Children’s Hospital of
Winnipeg, Winnipeg; Children’s Hospital London Health
Sciences Centre, London; McMaster Children’s Hospital,
Hamilton; The Hospital for Sick Children, Toronto; and
Children’s Hospital of Eastern Ontario, Ottawa).
Subjects eligible for study inclusion were (i) £18 years of
age; (ii) receiving or about to receive chemotherapy for cancer or conditioning for SCT, or received treatment within
the preceding 3 months (for chemotherapy patients),
6 months (for autologous SCT recipients), 2 years (for allogeneic SCT recipients), or receiving immunosuppressive
therapy for graft-versus-host disease for those ‡2 years postallogeneic SCT; and (iii) diagnosed with pH1N1 infection by
RT-PCR [using primers developed by the Centers for Disease
Control and Prevention (CDC; Atlanta, GA)17 or the
National Microbiology Laboratory (NML; Public Health
Agency of Canada, Winnipeg, MB),18 or the Astra influenza
Screen & Type (Astra Diagnostics, Hamburg, Germany)19]
of nasopharyngeal or flocked nasal mid-turbinate swabs
between May 1, 2009 and January 6, 2010.
Case details abstracted from health records were reported
on a standardized case report form. We collected patient
demographics, underlying conditions, treatment information, clinical manifestations, pandemic H1N1 vaccination
history, antiviral and antibiotic use, level of care required
and influenza-related complications. All centers obtained
research ethics board approval for the study.

Outcomes and definitions
North America experienced two waves of pH1N1 activity,
peaking in most locations around June and October
2009.20 Based on reporting of laboratory-confirmed pH1N1
hospitalized cases and deaths to the Public Health Agency
of Canada, we defined wave 1 as the period prior to August
30, 2009.21
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Severe outcomes examined were hospitalization, radiologically confirmed pneumonia (defined as new pulmonary
infiltrate on chest imaging associated with compatible clinical symptoms), intensive care unit (ICU) admission, need
for mechanical ventilation, and mortality. Potential predictors of severe outcomes were identified from the literature
or based on clinical experience and were defined a priori.
Other complications of interest that developed between
symptom onset and resolution were classified as respiratory
complications, extra-respiratory complications or microbiologically confirmed infections. Extra-respiratory complications were further subcategorized into hematologic or nonhematologic complications. Hematologic complications of
interest were neutropenia (absolute neutrophil count
<500 ⁄ mm3), lymphopenia (<500 ⁄ mm3), and thrombocytopenia (<50 000 ⁄ mm3). Non-hematologic complications
specifically sought for included clinical diagnoses of sepsis
(hypotension requiring fluid bolus or inotrope administration), pericarditis ⁄ myocarditis, myositis (elevated creatine
phosphokinase), encephalitis, and hepatitis (aspartate aminotransferase or alanine aminotransferase > twice the
upper limit of normal for age).
Obesity and underweight were covariates of interest and
were examined for children at least 2 years of age. Obesity
was defined as a body mass index (BMI) ‡ 95th percentile,
and underweight was defined as BMI < 5th percentile
based on the gender- and age-specific BMI reference from
Centers for Disease Control and Prevention.22 Children
<2 years were not included in this analysis because of
uncertainty in how to categorize children in this age-group.
Reflecting the recommendations of the Advisory Committee on Immunization Practices,23 full vaccination with
pH1N1 vaccine for children 6 months to <9 years was
defined as receipt of two vaccine doses separated by at least
4 weeks with dose 2 received ‡14 days prior to illness
onset. Those who received only one dose ‡14 days before
illness onset were classified as partially vaccinated. Children
aged 9–18 years were considered fully vaccinated with
receipt of one vaccine dose ‡14 days prior to illness onset.

Statistical considerations
Standard descriptive statistics were used to summarize data
on the study population. For all statistical testing, only the
first pH1N1 episode was included in cases with multiple
episodes within the same child because these episodes cannot be considered independent. Comparisons of data categorized by hospitalization versus no hospitalization,
presence or absence of radiologically confirmed pneumonia, and pandemic wave (wave 2 versus 1) were made using
the Mann–Whitney test for continuous variables and the v2
or Fisher’s exact test as appropriate for categorical variables. We performed univariate and multivariable linear or
logistic regression, as appropriate, to adjust for potential
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confounding variables and to identify independent predictors of severe outcomes. We considered for the multivariable
models all variables with P values <0Æ1 in univariate analysis and retained in the final model all variables with an
adjusted P-value <0Æ05. All tests were two-sided, and a P
value <0Æ05 was considered statistically significant. Data
were analyzed by spss statistical software (version 16Æ0,
SPSS Inc, Chicago, IL, USA).

Results
We identified a total of 102 episodes of laboratory-confirmed
pH1N1 infection in 100 children with 100 unique first episodes. Unique episodes were distributed in two distinct
waves: 19 in wave 1 prior to August 29, 2009, and 81 in wave
2 from August 30, 2009 onward. In total, 51 ⁄ 99 were hospitalized (information missing in one child) and 10 ⁄ 100 were
diagnosed with radiologically confirmed pneumonia.

Patient characteristics
Patient characteristics are illustrated in Table 1, and results
are stratified by whether children required hospitalization
or was diagnosed with pneumonia. Median age was
8Æ7 years, and males comprised 58Æ0% of cases. Cancer
diagnoses at the time of pH1N1 infection were leukemia
(63Æ0%), solid tumor (22Æ0%), lymphoma (8Æ0%), and
brain tumor (7Æ0%). Of these patients, 4 (4Æ0%) had refractory disease, 12 (12Æ0%) had relapsed disease, and 2 (2Æ0%)
had a secondary malignancy. 82 (82Æ0%) were receiving
chemotherapy around the time of pH1N1 infection, and 20
(20Æ0%) had undergone either autologous (n = 8) or allogeneic (n = 12) SCT. Obesity was documented in 21 ⁄ 98
children ‡2 years, while two children were classified as
underweight. Corticosteroids were part of anticancer therapy in 38 (38Æ0%) patients. Of 18 children who received
pH1N1 vaccine in the second wave, only one was fully
vaccinated at the onset of pH1N1 illness.

Table 1. Patient characteristics

Male gender
Age, y, median (IQR)
Age-group
0–4 years
5–9 years
‡10 years
Cancer diagnosis
Leukemia
Lymphoma
Solid tumor
Brain tumor
Stem cell transplant
Autologous
Allogeneic
Any comorbidity
Asthma or chronic lung disease
Obesity (excludes children <2 years)
ANC <500 ⁄ mm3 at pH1N1 diagnosis
Receiving corticosteroids
pH1N1 vaccination
Fully or partially vaccinated
Not vaccinated**
Early antiviral therapy
(within 24 hours)***
(within 48 hours)***

Overall
(n = 100)

Hospitalized
(n = 51)*

Not hospitalized
(n = 48)*

58 (58Æ0)
8Æ7 (5Æ0–13Æ0)

30 (58Æ8)
6Æ5 (4Æ3–10Æ4)

27 (56Æ2)
10Æ6 (6Æ0–15Æ2)

25 (25Æ0)
35 (35Æ0)
40 (40Æ0)

18 (35Æ3)
19 (37Æ3)
14 (27Æ5)

6 (12Æ5)
16 (33Æ3)
26 (54Æ2)

63 (63Æ0)
8 (8Æ0)
22 (22Æ0)
7 (7Æ0)

27 (52Æ9)
6 (11Æ8)
14 (27Æ5)
4 (7Æ8)

36 (75Æ0)
2 (4Æ2)
7 (14Æ6)
3 (6Æ2)

8 (8Æ0)
12 (12Æ0)
12 (12Æ0)
6 (6Æ0)
21 ⁄ 98 (21Æ4)
26 ⁄ 93 (28Æ0)
38 (38Æ0)
(n = 79)
6 (7Æ6)
73 (92Æ4)

6 ⁄ 12 (50Æ0)
6 ⁄ 12 (50Æ0)
7 (13Æ7)
4 (7Æ8)
10 ⁄ 49 (20Æ4)
22 ⁄ 49 (44Æ9)
17 (33Æ3)
(n = 41)
4 (9Æ8)
37 (90Æ2)

2 ⁄ 8 (25Æ0)
6 ⁄ 8 (75Æ0)
5 (10Æ4)
2 (4Æ2)
10 ⁄ 48 (20Æ8)
4 ⁄ 43 (9Æ3)
21 (43Æ8)
(n = 37)
2 (5Æ4)
35 (94Æ6)

36 ⁄ 85 (42Æ4)
49 ⁄ 85 (57Æ6)

16 ⁄ 44 (36Æ4)
22 ⁄ 44 (50Æ0)

20 ⁄ 40 (50Æ0)
27 ⁄ 40 (67Æ5)

P

0Æ796
0Æ003
0Æ008

Pneumonia
(n = 10)

No pneumonia
(n = 90)

6 (60Æ0)
7Æ2 (5Æ9–9Æ8)

52 (57Æ8)
8Æ8 (4Æ6–13Æ2)

1 (10Æ0)
7 (70Æ0)
2 (20Æ0)

24 (26Æ7)
28 (31Æ1)
38 (42Æ2)

6
0
3
1

57 (63Æ3)
8 (8Æ9)
19 (21Æ1)
6 (6Æ7)

0Æ128

P

1Æ000
0Æ527
0Æ050

0Æ712
(60Æ0)
(0Æ0)
(30Æ0)
(10Æ0)

0Æ373

–

0Æ614
0Æ679
0Æ959
<0Æ001
0Æ287
0Æ678

0 (0Æ0)
0 (0Æ0)
1 (10Æ0)
1 (10Æ0)
1 ⁄ 10 (10Æ0)
7 (70Æ0)
4 (40Æ0)
(n = 10)
1 (10Æ0)
9 (90Æ0)

8 ⁄ 20 (38Æ1)
12 ⁄ 20 (60Æ0)
11 (12Æ2)
5 (5Æ6)
20 ⁄ 88 (22Æ7)
19 (22Æ9)
34 (37Æ8)
(n = 69)
5 (7Æ2)
64 (92Æ8)

1Æ000
0Æ478
0Æ684
0Æ004
1Æ000
0Æ569

0Æ207
0Æ104

4 ⁄ 10 (40Æ0)
4 ⁄ 10 (40Æ0)

32 ⁄ 75 (42Æ7)
45 ⁄ 75 (60Æ0)

0Æ873
0Æ229

Data are n (%) unless otherwise indicated. ANC, absolute neutrophil count. Bold values in tables indicate P-values lower than the significance level
a = 0.05.
*
Indicates that hospitalization status was not available for one child.
**
Includes vaccination received after or <14 days prior to onset of illness.
***
From symptom onset to treatment initiation.
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Table 2. Clinical manifestations at presentation and during the
course of the influenza illness

Fever
Maximum temperature,
C, mean (SD)
Rhinorrhea
Sore throat
Cough
Hemoptysis
Wheezing
Respiratory distress
Rash
Headache
Myalgia
Abdominal symptoms*
Fatigue
Irritability
Altered level of
consciousness
Seizure
*

At
presentation
(n = 100)

During
illness
(n = 100)

n

n

%

%

84
84Æ0
38Æ8 (0Æ6)

88
88Æ0
38Æ9 (0Æ7)

46
22
80
0
3
2
6
13
12
24
20
3
1

46Æ0
22Æ0
80Æ0
0Æ0
3Æ0
2Æ0
6Æ0
13Æ0
12Æ0
24Æ0
20Æ0
3Æ0
1Æ0

46
26
85
1
6
4
7
15
13
28
26
3
1

46Æ0
26Æ0
85Æ0
1Æ0
6Æ0
4Æ0
7Æ0
15Æ0
13Æ0
28Æ0
26Æ0
3Æ0
1Æ0

0

0Æ0

0

0Æ0

Includes nausea and ⁄ or vomiting and ⁄ or diarrhea.

Clinical presentation, course, and management
Table 2 illustrates symptoms at presentation of pH1N1 and
during the illness course. The most commonly reported presenting symptoms were fever (84Æ0%) and cough (80Æ0%);
24Æ0% had abdominal pain, nausea, vomiting, and ⁄ or
diarrhea. Median interval between symptom onset and clinical encounter was 1 day [interquartile range (IQR), 0–2].
The treatment and clinical course of pH1N1 infection
are presented in Tables 1 and 3. Antiviral therapy was prescribed to most patients during the pandemic, with more
frequent antiviral use in wave 2 than 1 (P = 0Æ001). Overall, antiviral therapy was extended beyond the standard
5-day course for 17 (19Æ5%) patients, 12 of whom received
a 10-day course. Antibiotics were given in 56 (56Æ0%) cases.
Median duration of symptoms (defined as the interval
between onset of any symptom and resolution of all symptoms) and that of fever was 12Æ5 and 2 days, respectively.
We were able to determine the duration of shedding of
pH1N1 virus for 35 patients, the median of which was
46 days. In the 22 patients for whom both duration of
symptoms and viral shedding were available, 13 continued
to shed virus after symptom resolution. The median duration of viral shedding did not differ significantly based on
whether or not the patient was hospitalized (63 days [IQR,
14–88Æ5] versus 44 days [IQR, 19–78Æ5]; P = 0Æ986) or diag-
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nosed with pneumonia (65Æ5 days [IQR, 20Æ25–95Æ75]
versus 44 days [IQR, 14–85]; P = 0Æ836). The median duration of viral shedding was, however, significantly shorter in
wave 2 of the pandemic (38 days [IQR, 13–70] versus 98.5
days [IQR, 28.25–157.25]; P = 0Æ034). As antiviral use differed between wave 1 and 2, we explored the possible confounding effects of different aspects of antiviral
prescription (antiviral treatment versus no treatment, antiviral treatment within 24 hours versus after 24 hours of
symptom onset, extended versus standard antiviral course)
and other factors on the logarithm of length of viral shedding in linear regression analyses (Table 4). After multiple
regression analysis, we found that an extended antiviral
treatment course, but not wave 2, was significantly associated with shortened duration of viral shedding.
In terms of other complications, 2 experienced asthma
exacerbation. Upper respiratory tract disease associated
with pH1N1 infection were otitis media (n = 4), sinusitis
(n = 2), and croup (n = 1). Hematologic abnormalities
were neutropenia (n = 32), lymphopenia (n = 29), and
thrombocytopenia (n = 17). Of the 11 patients classified as
having a non-hematologic, extra-respiratory complication,
nine had hepatitis. Microbiologically confirmed bacterial
infection was documented in two cases (one coagulase-negative staphylococcus bacteremia and one Staphylococcus
aureus cellulitis). Infection with a herpes group virus during the pH1N1 illness was reported in two patients (one
herpes simplex virus and one Epstein–Barr virus), both
managed as outpatients. Of the 82 patients scheduled for
chemotherapy or conditioning for SCT, 43 had their chemotherapy or conditioning delayed (n = 23), modified
(n = 5), or stopped ⁄ canceled (n = 11).

Severe outcomes of pH1N1
As previously described, 51 children were hospitalized and
10 had radiologically confirmed pneumonia (Table 3).
The median duration of hospitalization was 5 days (IQR,
3-13 days); for those with absolute neutrophil count
(ANC) < 500 cells ⁄ mm3 at pH1N1 diagnosis, it was 6 days
(IQR, 4–11Æ5 days). Overall, few patients developed critical
illness. There was no mortality; one child was admitted to
ICU for pneumonia requiring ‡60% supplemental oxygen
and continuous positive airway pressure by face mask but
not intubation or mechanical ventilation; and one child
had pneumonia resulting in ‡60% supplemental oxygen
therapy but did not require ICU admission.
Table 5 displays univariate and multivariable analyses for
predictors of pH1N1-associated hospitalization and pneumonia. In univariate analyses, children <5 years were more
likely to be hospitalized (P = 0Æ003) and those aged
5–9 years trended toward being more likely to have
pneumonia (P = 0Æ063), compared to children ‡10 years.
Neutropenia at pH1N1 diagnosis was associated with
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Table 3. Clinical course, treatment, and complications

Clinical course and management
Days of symptoms, median (IQR)
Days of fever, median (IQR)
Days of viral shedding, median (IQR)
Antiviral therapy
Early antiviral therapy
Within 24 hours of symptom onset
Within 48 hours of symptom onset
Antiviral duration
Standard (5 days)
Extended (>5 days)
Antibiotic treatment
Oxygen supplementation
Respiratory complications*
Upper respiratory tract
Asthma exacerbation
Extra-respiratory complications
Hematologic
Non-hematologic
Laboratory-confirmed infections
Bacterial
Fungal
Viral
Alteration of chemotherapy**
Severe outcomes
Hospitalization
Duration, d, median (IQR)
Pneumonia***
ICU admission
Need for mechanical ventilation
Death

Overall (n = 100)

Wave 1 (n = 19)

Wave 2 (n = 81)

P

12Æ5 (6–18)
2 (1–4)
46 (14–85)
89 (89Æ0)

18 (7–19Æ25)
2 (1–3)
98Æ5 (28Æ25–157Æ25)
12 (63Æ2)

10 (6–16Æ75)
2 (1–4)
38 (13–70)
77 (95Æ1)

0Æ149
0Æ443
0Æ034
0Æ001

36 ⁄ 85 (42Æ4)
49 ⁄ 85 (57Æ6)

2 ⁄ 11 (18Æ2)
6 ⁄ 11 (54Æ5)

34 ⁄ 74 (45Æ9)
43 ⁄ 74 (58Æ1)

0Æ108
1Æ000

70 ⁄ 87 (80Æ5)
17 ⁄ 87 (19Æ5)
56 (56Æ0)
4 (4Æ0)
9 (9Æ0)
7 (7Æ0)
2 (2Æ0)
39 (39Æ0)
50 (50Æ0)
11 (11Æ0)
5 (5Æ0)
2 (2Æ0)
1 (1Æ0)
2 (2Æ0)
43 ⁄ 82 (52Æ42)

8 ⁄ 11 (72Æ7)
3 ⁄ 11 (27Æ3)
9 (47Æ4)
2 (10Æ5)
1 (5Æ3)
1
0
8 (42Æ1)
13
5
1 (5Æ3)
0
1
0
9 ⁄ 17 (52Æ9)

62 ⁄ 76 (81Æ6)
14 ⁄ 76 (18Æ4)
47 (58Æ0)
2 (2Æ5)
8 (9Æ9)
6
2
31 (38Æ3)
37
6
4 (4Æ9)
2
0
2
34 ⁄ 65 (52Æ3)

0Æ443

51 ⁄ 99 (51Æ5)
5 (3–13)
10 (10Æ0)
1 (1Æ0)
0 (0Æ0)
0 (0Æ0)

10 (52Æ6)
8 (4–68Æ5)
2 (10Æ5)
0 (0Æ0)
–
–

41 ⁄ 80 (51Æ2)
5 (3–10Æ75)
8 (9Æ9)
1 (1Æ2)
–
–

0Æ914
0Æ143
1Æ000
1Æ000
–
–

0Æ400
0Æ162
1Æ000

0Æ758

1Æ000

0Æ963

Data are n (%) unless otherwise indicated. Bold values in tables indicate P-values lower than the significance level a = 0.05.
*
Excludes radiologically confirmed pneumonia.
**
Denominators exclude patients not scheduled for chemotherapy.
***
Radiologically confirmed.

None required ventilation, inotropes, dialysis, or extracorporeal membrane oxygenation.

hospitalization (P < 0Æ001) and pneumonia (P = 0Æ005), as
was neutropenia detected at any time during the illness
(P < 0Æ001 and P = 0Æ015, respectively). We did not collect
data on lymphopenia at pH1N1 diagnosis, but lymphopenia
detected at any time during the illness was not associated
with hospitalization or pneumonia. Multiple logistic
regression revealed that age category and neutropenia (both
at diagnosis and during the illness) were significant
independent predictors of hospitalization, with children
<5 years at highest risk. Neutropenia, but not age, was a
significant predictor of pneumonia in multiple logistic
regression analysis. The models that included age and
neutropenia at diagnosis fit the observed data well
(Hosmer–Lemeshow P = 0Æ955 and 0Æ778 for hospitalization and pneumonia, respectively) and discriminated
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well between those who were and were not hospitalized
[c-index, 0Æ767 (95% CI, 0Æ670–0Æ864)] as well as between
children with and without pneumonia [c-index, 0Æ839
(95% CI, 0Æ735–0Æ942)].

Discussion
This study resulted in several important observations. First,
pH1N1 infection was uncomplicated in most children with
cancer although commonly interrupted anticancer therapy.
Second, neutropenia was an important predictor of hospitalization as well as pneumonia. Third, antiviral prescription increased significantly during wave 2 of the pandemic.
Finally, prolonged viral shedding often persisted after
symptom resolution, and an extended antiviral treatment
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Table 4. Duration of viral shedding and potential predictive factors

Log10 (days of viral shedding)

Male gender
Age (years)
Receiving
corticosteroids
ANC < 500 ⁄ mm3 at
diagnosis of pH1N1
ALC < 500 ⁄ mm3
during illness course
Fully or partially
vaccinated
Hospitalized versus
not hospitalized
Pneumonia versus no
pneumonia
Pandemic wave
(wave 2 versus 1)
Antiviral therapy
Early antiviral therapy
Within 24 hours of
symptom onset
Within 48 hours of
symptom onset
Antiviral duration
(extended versus
standard)

Univariate
analysis

Multivariable
analysis

Coefficient b
(SE)
P

Coefficient b
(SE)
P

)0Æ07 (0Æ16)
)0Æ01 (0Æ02)
0Æ13 (0Æ17)

0Æ685 –
0Æ578 –
0Æ441 –

–
–
–

0Æ13 (0Æ21)

0Æ529 –

–

)0Æ03 (0Æ18)

0Æ893 –

–

)0Æ19 (0Æ36)

0Æ600 –

–

)0Æ03 (0Æ16)

0Æ857 –

–

0Æ05 (0Æ25)

0Æ837 –

–

)0Æ35 (0Æ18)

0Æ059 )0Æ25 (0Æ20)

0Æ219

)0Æ26 (0Æ25)

0Æ304 –

–

0Æ04 (0Æ18)

0Æ809 –

–

0Æ05 (0Æ17)

0Æ754 –

–

)0Æ36 (.017)

0Æ048 )0Æ37 (0Æ17)

0Æ041

ALC, absolute lymphocyte count. Bold values in tables indicate
P-values lower than the significance level a = 0.05.

course >5 days was associated with shortened length of
viral shedding.
In our cohort, 51Æ5% of patients were hospitalized and
10% developed lower respiratory tract infection. Although
only one patient was admitted to the ICU and none died,
52Æ4% of those scheduled for chemotherapy or conditioning had treatment modified or held. These results are comparable to those of modest-sized case series of pediatric
cancer patients from Italy,13 Texas,12 Jordan,14 and Turkey.15 In contrast, a Brazilian study found that 8 ⁄ 14 pediatric cancer patients hospitalized with pH1N1 required ICU
admission and ventilator support. This is consistent with
the high rate of severe complications from pH1N1 infection in the general Brazilian population.16 Potential explanations for the discrepant findings of this study include
increased predisposition to severe pH1N1 infection in the
Brazilian population owing to host genetic and ⁄ or socioeconomic factors.
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Several factors may contribute to the generally favorable
outcome of pH1N1 infection in cancer patients. First, parents of children with cancer are likely to seek prompt medical attention in the presence of fever, resulting in early
diagnosis and antiviral treatment. A meta-analysis of 11
randomized controlled trials (RCTs) showed that oseltamivir treatment was associated with a reduced risk of lower
respiratory tract complications in adolescents and adults
with flu symptoms.24 A recent RCT demonstrated that
early antiviral treatment in children aged 1–3 years reduced
illness duration and incidence of otitis media.25 Second,
increased cytokine and chemokine plasma levels have been
shown to be markers of critical illness with pH1N1 infection, suggesting that immunopathology may contribute to
disease severity.26,27 It is possible that the relatively benign
course of illness in children with cancer is partly related to
decreased cytokine and chemokine production related to
immune suppression. Third, high levels of cross-reacting
but non-neutralizing antibodies that result from previous
seasonal influenza exposures, leading to immune complexmediated pulmonary disease, have been advanced as a
novel biological mechanism of severe cases of pH1N1 in
middle-aged individuals.28 Pediatric cancer and SCT
patients have impaired serum antibody responses to both
seasonal influenza vaccination and natural infection and
would, therefore, likely be protected from this mechanism
of severe pH1N1 disease. Finally, concurrent bacterial infection has been documented in 29% of lung tissue specimens
from fatal human cases of pH1N1.29 Neutropenia was an
independent predictor of pneumonia in our study, and
neutropenia, in association with fever, would trigger hospitalization and broad-spectrum antibiotic therapy resulting
in early treatment of established or subclinical bacterial
lower respiratory tract infection along with more intensive
supportive therapy.
It is possible that neutropenia was merely a surrogate for
profound lymphopenia that has been shown to correlate
with the risk of influenza-associated lower respiratory tract
infection 30,31 and that the lack of association of concurrent
lymphopenia with pneumonia in our study reflected a higher
cut-off point compared to previous studies demonstrating
association (<500 ⁄ mm3 versus <100–200 ⁄ mm3).30,31 More
detailed analysis of ANC and absolute lymphocyte count
(ALC) in relation to the pattern of radiographic changes
(viral versus bacterial) in future studies could provide
further insight. In addition to neutropenia, our study
indicated that younger age (particularly those <5 years)
was associated with hospitalization for pH1N1 infection.
This is consistent with reported rates of pH1N1-associated
hospitalization in the general pediatric population, being
highest for children <5 years and especially for those
<12 months.32 Morbid obesity has been associated with
hospitalization and death from pH1N1 infection in
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Table 5. Factors associated with hospitalization and radiologically confirmed pneumonia

Hospitalization

Age-group*
0–4 years
5–9 years
‡10 years
ANC <500 ⁄ mm3 at pH1N1 diagnosis
ANC <500 ⁄ mm3 during illness course
ALC <500 ⁄ mm3 during illness course

Pneumonia

Univariate analysis

Multivariable analysis

Univariate analysis

Multivariable
analysis

OR (95% CI)

OR (95% CI)

OR (95% CI)

P

OR (95% CI)

P

0Æ8 (0Æ1–9Æ2)
4Æ8 (0Æ9–24Æ6)
Reference
7Æ9 (1Æ9–33Æ4)
5Æ9 (1Æ4–24Æ8)
1Æ6 (0Æ4–6Æ2)

0Æ078
0Æ852
0Æ063
–
0Æ005
0Æ015
0Æ495

0Æ5 (0Æ04–6Æ7)
4Æ4 (0Æ8–25Æ4)
Reference
9Æ2 (2Æ0–42Æ1)
6Æ4 (1Æ4–28Æ2)
–

0Æ086
0Æ626
0Æ099
–
0Æ004
0Æ015
–

5Æ6 (1Æ8–17Æ2)
2Æ2 (0Æ9–5Æ6)
Reference
7Æ9 (2Æ5–25Æ7)
6Æ8 (2Æ4–18Æ9)
1Æ5 (0Æ6–3Æ5)

P

0Æ010
0Æ003
0Æ095
–
<0Æ001
<0Æ001
0Æ401

4Æ9 (1Æ4–17Æ1)
2Æ2 (0Æ7–6Æ2)
Reference
8Æ1 (2Æ4–27Æ1)
7Æ0 (2Æ4–20Æ4)
–

P

0Æ041
0Æ012
0Æ155
–
0Æ001
<0Æ001
–

ORs generated by logistic regression.
ANC, absolutely neutrophil count; ALC, absolute lymphocyte count; CI, confidence interval; OR, odds ratio.
*
ORs and P values displayed in multivariable models are those generated with inclusion of ANC <500 ⁄ mm3 at pH1N1 diagnosis as a predictor
variable. Bold values in tables indicate P-values lower than the significance level a = 0.05

adults.33,34 In contrast, in children, hospitalization appears
to be associated with being underweight, and death has not
been associated with BMI category.33 Consistent with this
observation was the relatively uncomplicated clinical course
of our cohort, which included a large number of obese but
only two underweight children.
While antiviral treatment was prescribed to most patients
in our study, its use was significantly less frequent during
wave 1, when only 63Æ2% were treated with oseltamivir.
This occurred despite the existence of antiviral therapy
guidelines predating the pandemic that recommended
treatment for children at high risk of severe influenza,
including those with cancer.35,36 The gap in adherence to
such guidelines during wave 1 suggests that either guideline
dissemination was suboptimal or that clinicians were further risk-stratifying patients for antiviral therapy. The
increased use of antivirals during wave 2 in our cohort
might have reflected emergence of reports in the literature
and media of severe pH1N1 cases.
Our study demonstrated that cancer and SCT patients
had prolonged viral shedding, which has also been
observed in studies of cancer patients with seasonal influenza.37 A recent report of cancer patients hospitalized with
pH1N1 also documented prolonged excretion of virus, in
which 5 ⁄ 10 mechanically ventilated patients shed virus for
‡11 days.16 Given that severe respiratory illness has also
been associated with delayed pH1N1 clearance,38 the
authors acknowledged that they could not determine
whether the persistent pH1N1 shedding in their study was
attributed to the severity of pH1N1 disease, the underlying
immunocompromised state, or both. Our data indicate that
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an immunocompromised state is an important contributor
to prolonged excretion of pH1N1 virus. Therefore, pH1N1infected cancer patients could potentially serve as mixing
vessels, when infected with seasonal influenza viruses, for
genetic reassortment and generation of a more virulent
influenza subtype.39
Another important observation was that viral shedding
often extended far beyond the symptomatic period. This
finding may have important infection control implications.
While isolation of the symptomatic patient is clear, the role
of asymptomatic viral shedding in transmission is less well
studied and recommendations for isolation of these
patients are variable.40,41 If asymptomatic shedding can
result in the spread of influenza, then it would be important to practice strict infection control practices until laboratory confirmation of viral clearance in hospitalized
patients and for outpatients returning to the ambulatory
clinic for continuing care regardless of symptoms.
We also found that treatment with an extended course
of oseltamivir was associated with a shorter duration of
viral shedding. While early use of oseltamivir has been
associated with reduction in days of viral shedding,38 we
are not aware of previous data demonstrating a correlation
between length of antiviral treatment and duration of viral
shedding. Some experts have advocated a 10-day course as
the standard duration for immunocompromised patients42
although the Advisory Committee on Immunization Practices merely states that ‘longer treatment regimens might
be necessary in severely ill hospitalized patients or persons
with immunosuppression’.43 These factors, along with the
generally mild clinical course, may have accounted for the
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infrequent use of extended antiviral treatment in the study.
Our findings, if confirmed in future studies, would lend
further support to a recommendation for longer treatment
regimens and may have beneficial infection control implications. However, any potential benefits from prolonged
antiviral therapy would have to be balanced against the risk
of selection for resistance mutations.44
Limitations of the study include its retrospective design
and inability to calculate population-based rates. Based on
its retrospective nature, our ability to determine whether the
hematologic complications were attributable to influenza
infection or to chemotherapy was limited, and our results
may be affected by unobserved confounders or insufficient
adjustment for observed confounders. The precision in our
estimate of the duration of viral shedding may have been
limited given that follow-up influenza testing was performed
at the clinicians’ discretion. The extent of prolonged viral
shedding may have been overestimated by overrepresentation of serial sampling in patients with longer courses. We
did not capture data on the duration of individual symptoms and therefore were not able to identify those which
could potentially be used to guide optimal retesting and
treatment. Although larger than previous studies of pediatric
cancer and SCT patients, our sample size was still relatively
small. Some of our metrics of influenza severity such as hospitalization, length of hospital stay, and ICU admission may
be influenced by variation in clinical practice across centers
as well as non-medical factors such as publicity surrounding
the pandemic and bed availability.
In conclusion, pH1N1 infection was associated with an
uncomplicated course in most pediatric cancer and SCT
patients but commonly altered scheduling of chemotherapy
or transplant conditioning. Although neutropenia was an
independent predictor of radiologically confirmed pneumonia, it is unclear whether it can be used as a criterion separate from lymphopenia for decision-making regarding
cancer treatment modification given the limitations in our
analysis of lymphopenia as a risk factor. Despite the
uncomplicated course in most, viral shedding was prolonged and often continued after symptom resolution. Prospective studies evaluating the effects of extended antiviral
treatment on viral shedding in cancer and SCT patients,
while addressing the limitations in this study, could have
an important bearing on infection control practices and
treatment guidelines.
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